Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06408194 · ClinicalTrials.gov registry record · Phase 1
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
A Phase 1 study of Leukemia and Acute Lymphoblastic Leukemia, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06408194 is a Phase 1 study of Leukemia and Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 20 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06408194, a Phase 1 study of Leukemia and Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.
Conditions Studied
Interventions
- DRUG CD22CART infusion
- DRUG Tisagenlecleucel
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06408194
The ClinicalTrials.gov registry entry for NCT06408194 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which CD22CART infusion is the first listed.
NCT06408194 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06408194 about?
NCT06408194 is a clinical study titled "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies". The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to ...
What is the current status of trial NCT06408194?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-05-13. Estimated completion is 2026-07.
What conditions does trial NCT06408194 study?
This clinical trial studies the following conditions: Leukemia, Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06408194?
The interventions under investigation include: CD22CART infusion (DRUG), Tisagenlecleucel (DRUG).
Who is sponsoring clinical trial NCT06408194?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06408194 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.